SEARCH RESULTS

349480 RESULTS

Scientists Grapple with How to Outsmart TREM2, the Trickster

CONFERENCE COVERAGE 2025-04-17 Conference Coverage Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating this receptor is an enticing therape

TREM2: A Chill Pill for Neurons?

CONFERENCE COVERAGE 2025-04-17 Conference Coverage TREM2 created quite the buzz at this year’s AD/PD meeting, held April 1-5 in Vienna. In the wake of a TREM2 agonist’s demise, scientists presented optimistic findings from early phase trials of a fresh batch of agonists. Juxtaposing th

Moving Target: New Biology Casts TREM2 as a Shifty Mark

CONFERENCE COVERAGE 2025-04-17 Conference Coverage Ever since the discovery of AD risk-stoking variants of TREM2, the microglial receptor has given scientists seeking to nail down its function a run for their money. It binds many ligands, supports manifold microglial functions, and see

Neuroimaging in ADRD T32 Postdoctoral Fellow

JOB 2025-04-17 Employer University of Pennsylvania Contact Research Statement: please provide a 1-page specific aims format page that describes a research project using neuroimaging in ADRD and specify how it relates to one of the 3 specializations described above.     

Cheng Hu on Risvodetinib

COMMENT IkT-148009 is a patent-busting product of Imatinib, which is known for having poor CNS penetration. I wonder what is the CNS exposure of IkT-148009 in humans, and if the clinical failure is caused by poor exposure, not the efficacy of the drug. cheng_4182

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
    1. From
      To

TYPE
AlzAntibodiesAlzBiomarkerAlzRiskBrain BanksGeneticsAlzGeneHEXMutationsProtocolsResearch ModelsTherapeutics